Arcus Biosciences Inc RCUS

$17.77 -1.03 (-5.48%)

Valuation

Market cap
2,707,031,000
Revenue TTM
$247,000,000
Net income TTM
$-353,000,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-142.92%
Debt to equity
0.28

Trading

Volume
1,097,936
Avg volume
2,023,102
Day's range
$17.76 – $18.65
Shares out
143,991,000
Stochastic %K
13%
Beta
1.04
Analysts
Strong Buy
Price target
$39.17

Price

Company profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody....

Show more

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Industry
Biotechnology
Sector
Healthcare
Phone
510 694 6200
Website
https://arcusbio.com
Address
3928 Point Eden Way, Hayward, United States

Latest news

Stocktwits

Merlintrader Nov 12, 7:48 PM
New on Merlintrader: the $RCUS stock hub. Arcus had 694 million dollars of cash at Sept 30, plus 269.7 million net from its October offering. The PRISM-1 Phase 3 interim analysis in pancreatic cancer is expected in Q4 2026. Full $RCUS stock hub: https://www.merlintrader.com/arcus-biosciences-rcus-stock-hub/ Not investment advice.
0 replies
bden21 Nov 6, 3:11 AM
$RCUS trash
0 replies
stcks Nov 4, 9:53 PM
$RCUS https://x.com/biotechtv/status/2113013742782787847/video/1?s=46 Go to the 2:00 min mark
0 replies
stcks Nov 4, 9:46 PM
$RCUS RCUS Q3 after the close (medium impact, mixed to neutral). Arcus release Revenue was $9M, down from $26M a year ago, and the net loss was $128M. It had $694M in cash at quarter end, plus $288M gross from the October stock sale. Arcus says that funds operations into 2029. Its second-line Phase 3 kidney cancer trial, PEAK-1, should finish enrolling in 2 to 3 months. PEAK-20, its first-line Phase 3 trial, is still on track to start by year-end. More mature ARC-20 data is due in 2027. With no pipeline surprises and the cash already raised, this probably won't move the stock much. RCUS closed up 2.38% at $19.36.
0 replies
stcks Nov 4, 3:49 AM
$RCUS 🤮
0 replies
stcks Nov 3, 11:48 AM
$RCUS Q3 2026 results, release only per company IR calendar (1:05 PM PT). Source: https://investors.arcusbio.com/investors-and-media/events-and-presentations/events-calendar/event-details/2026/Arcus-Biosciences-Third-Quarter-2026-Earnings-Release-Only-2026-3gWwsIYH3h/default.aspx
0 replies
stcks Nov 3, 11:47 AM
$RCUS Management fireside chat at Jefferies Global Healthcare Conference London, 5:00 PM GMT. Source: https://www.businesswire.com/news/home/20261102336316/en/
0 replies
stcks Nov 3, 6:04 AM
$RCUS RCUS options (11/02/26): 30-day ATM implied volatility 101.9%; the 11/20 options imply a move of about ±$4.19 (23.5%); open interest is call-heavy (put/call OI 0.60, volume 3.81); max pain for 11/20 is $25.00 vs spot $17.85. No unusual volume. IV rank/percentile need 20+ nightly snapshots (history starts 10/08/26).
0 replies